Q3 BioMeter Shows Reemergence of Late Stage Deals -
The average BioMeter value in the third quarter of 2014 was $43.7 million, an increase from the $30.4 million value in the same quarter in 2013, and a slight increase from the blockbusterexcluding value of $41.7 million in the second quarter of 2014. When the two second quarter blockbuster deals (the $1 billion Merck/Bayer deal for a family of soluble guanylate cyclase modulators, and the $710 million Celgene/Nogra deal for a Phase 2 Crohn’s disease drug) are included, the third quarter BioMeter is down compared to $143 million in the second quarter.
Leading the way in the third quarter were transactions for Phase 3 and approved products, with average BioMeter values of $83.3 million and $86.7 million, respectively. Even more striking this quarter was the number of deals in these categories, with seven announced Phase 3 transactions that disclosed up-front payments, and five announced transactions for approved products that disclosed up-front payments. The BioMeter values, combined with the relatively large numbers of transactions in these categories, are the strongest we’ve seen since we started reporting quarterly BioMeter values.
Please see full publication below for more information.